




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : G01N 33/543, 33/547, C12Q 1/68		A1	(11) International Publication Number: WO 95/16204
			(43) International Publication Date: 15 June 1995 (15.06.95)
(21) International Application Number: PCT/GB94/02680			(81) Designated States: CA, JP, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(22) International Filing Date: 7 December 1994 (07.12.94)			
(30) Priority Data: 9325100.7 7 December 1993 (07.12.93) GB			
(71) Applicant (for all designated States except US): UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW [GB/GB]; University Avenue, Glasgow G12 8QQ (GB).			
(72) Inventors; and (75) Inventors/Applicants (for US only): MORGAN, Hywel [GB/GB]; 3 Auldea Road, Beith, Ayrshire KA15 2BZ (GB). PRITCHARD, David, John [GB/GB]; 27 Hillhead Street, Glasgow G12 8PX (GB). COOPER, Jonathon, Mark [GB/GB]; 32 Duncan Avenue, Glasgow G14 9NH (GB).			
(74) Agent: MURGITROYD & COMPANY; 373 Scotland Street, Glasgow G5 8QA (GB).			

(54) Title: **SURFACE-PATTERNED DEVICE**

(57) Abstract

There is described a device which has a surface coated with a biomolecule in a pre-determined pattern. The molecule is attached to the surface via a photosensitive binding moiety itself attached to the surface via a linking moiety. Preferably the linking moiety is avidin or a derivative thereof and the photosensitive binding moiety is photobiotin or a derivative thereof. The pattern of binding of the biomolecule is determined by the selective irradiation of non-irradiation of the photosensitive binding moiety. In a preferred embodiment two or more different ligands are bound to the surface in a pre-determined pattern. The device according to the invention may be of use in multi-analyte sensors in molecular electronics, in directional propagation of cell growth and in altering the behaviour of cells. The device may also be used to bind nucleotides which are subsequently manipulated or used as a probe or template.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

1 "SURFACE-PATTERNED DEVICE"

2

3 The present invention relates to a device wherein
4 molecules are attached to a surface in a pre-determined
5 pattern. A process for producing such a device is also
6 disclosed.

7

8 Various applications in technology require a device to
9 have a surface which is coated with a molecule, such as
10 an organic molecule. Generally, a uniform layer of the
11 molecule required is bound to the surface. Optionally
12 the bound molecule may then be used to attach other
13 molecules to the surface.

14

15 Surfaces coated with biomolecules in this way have many
16 applications, for example in assays or diagnostic
17 tests. One popular assay is an immunoassay, involving
18 the use of antibodies to selectively bind to an antigen
19 of interest. Frequently, the antibody may be bound to
20 a surface giving a convenient diagnostic device. Other
21 applications where binding biomolecules to a surface is
22 useful includes the separation and purification of
23 biomolecules.

24

1 GB-A-2141544 discloses a method of binding biomolecules
2 to a surface in a particular pattern. The biomolecules
3 are bound via a photosensitive intermediate organic
4 molecule, such as N-(4-azido-2-nitrophenyl)-1,3-
5 diaminopropane. By using a mask, the photactivatable
6 organic molecule is light activated in specific areas
7 only and the biomolecule is subsequently only able to
8 bind to those areas.

9
10 The process of GB-A-2141544 may result in non-specific
11 binding, since biomolecules other than the one of
12 interest may also be bound to the activated
13 photosensitive intermediate resulting in a poor quality
14 product. Problems in binding the molecules of interest
15 may also occur due to steric restrictions. Further,
16 the process described in GB-A-2141544 is dependent upon
17 covalent attachment of the photosensitive intermediate
18 organic molecule to the surface.

19
20 The present invention seeks to overcome the problems
21 encountered in the prior art and to provide patterning
22 of molecules upon a surface in a precise manner.

23
24 In one aspect, the present invention provides a device
25 having a surface, said surface having a ligand bound
26 thereto in a pre-determined pattern, the binding of
27 said ligand being determined by the irradiation or non-
28 irradiation of a photosensitive binding moiety attached
29 to said surface via a linking moiety.

30
31 The coated surface of the device is preferably capable
32 of producing measurable change. The change may be
33 detected by any suitable means, for example optically,
34 spectrophotometrically, piezoelectrically, calori-
35 metrically or by measuring magnetic field strength.

1 Desirably, the device of the present invention has a
2 surface on which at least two different ligands are
3 arranged thereon in a pre-determined manner.
4

5 The linking moiety must be able to be uniformly bound
6 to the surface of interest. Selection of the technique
7 to bind the linking moiety may thus depend upon the
8 chemical character of the surface. Furthermore the
9 linking moiety preferably has the function of
10 preventing or reducing non-specific binding. The
11 linking moiety may also be of utility in spacing out
12 the binding moiety to avoid steric hindrance problems
13 in binding the ligand. Preferably the linking moiety
14 may be orientated in a particular manner on the
15 surface.
16

17 The term "functional equivalent" is used herein to
18 refer to any modified version of a moiety which retains
19 the basic function of the moiety in its unmodified
20 form. As an example, it is well-known that certain
21 alterations in amino acid or nucleic acid sequences may
22 not affect the protein encoded by that molecule or the
23 function of the protein. It is also possible for
24 deleted versions of a molecule to perform a particular
25 function as well as the original molecule.
26 Even where an alteration does affect whether and to
27 what degree a particular function is performed, such
28 altered molecules are included within the term
29 "functional equivalent" provided that where the
30 function concerned is required for production of the
31 device according to the invention then this function is
32 performed sufficiently to render the device operational
33 within the degree of accuracy required for the ultimate
34 end use of the device.
35

1 Conveniently, the linking moiety is itself an organic
2 molecule. The linking moiety may be a macromolecule,
3 for example a macromolecule having a molecular weight
4 of at least 500Da, or the linking moiety may be a
5 biomolecule such as polypeptides or proteins, mono-,
6 di- or poly-saccharides, or functional equivalents
7 thereof. However, non-biological molecules are not
8 excluded and examples include polymers and other
9 organic molecules. Preferably, the linking moiety is a
10 polypeptide or protein, and particularly preferred
11 examples include avidin, streptavidin or functional
12 equivalents thereof.

13
14 The linking moiety may be bound to the surface by any
15 type of association, including non-covalent and
16 covalent binding, ionic interaction and intermolecular
17 associations such as hydrogen bonding, and Van der
18 Waals attractions. Non-covalent interactions may be
19 preferred in certain applications.

20
21 Alternatively, the linking moiety may be attached to
22 the surface by physical entrapment.

23
24 It may be desirable in certain applications to attach
25 the linking moiety to the surface so that substantially
26 all of the linking moieties are orientated in the same
27 or similar direction on at least part of the surface.

28
29 It is not necessary for the linking moiety to be
30 directly attached to the surface, and in some
31 circumstances the surface may be coated (optionally
32 several times) before the linking moiety is attached to
33 a layer thereof, usually the uppermost layer. Where
34 the linking moiety is attached to the surface by
35 entrapment in a carrier substance, it may be desirable

1 to coat the surface with an admixture of linking moiety
2 in the carrier substance, the carrier adhering to the
3 surface and physically entrapping the linking moiety.

4
5 The binding moiety may be any photosensitive entity
6 which binds to said linking moiety. As an example, the
7 binding moiety may be based on a biomolecule, such as a
8 protein, polypeptide, mono-, di- or poly-saccharide,
9 polynucleic acid and the like, or functional
10 equivalents thereof. Also suitable as the binding
11 moiety are small biological or non-biological molecules
12 such as a photosensitive derivatives of biotin (2-keto-
13 3,4-imidazolido-2-tetrahydrothiophen-n-valeric acid).
14 A suitable photosensitive derivative of biotin is the
15 molecule (N-(4-azido-2-nitrophenyl)-N'-(N-d-biotinyl-3-
16 aminopropyl)-N'-methyl-1,3-propanediamine), commonly
17 known as "photobiotin". Alternatively, the binding
18 moiety may be any protein or polypeptide (or functional
19 equivalent thereof) able to bind to the specific ligand
20 of interest. In this regard, mention may be made of
21 enzymes and antibodies which are suitable for use as
22 said binding moiety. In particular, photosensitive
23 antibodies (for example monoclonal antibodies) or
24 biotin are preferred.

25
26 It is essential that the binding moiety is
27 photosensitive, that is to say that the binding moiety
28 is sensitive to irradiation. The term "photosensitive"
29 is used herein to indicate that the binding moiety is
30 altered (physically and/or chemically) by exposure to
31 electro-magnetic radiation. Preferably, the binding
32 moiety is activated by electro-magnetic irradiation.
33 The binding moiety may be irradiated by any type of
34 light including visible light, UV light and infra-red
35 light.

1 Generally, irradiation of said binding moiety occurs in
2 pre-selected areas to impose the desired pattern
3 thereon. Selective irradiation may be achieved by any
4 known method, but one convenient way is to superimpose
5 a mask or screen of irradiation-absorbing or reflecting
6 material over the surface. The shape of the mask is
7 transferred into the surface by the alteration of
8 binding moieties exposed to the radiation. Other means
9 of selectively altering binding moieties include the
10 use of focused radiation or irradiation sources such as
11 lasers.

12
13 In one embodiment, irradiation causes activation of the
14 photosensitive binding moieties exposed to the
15 radiation. Only the activated binding moieties are
16 able to bind to the ligand. In this embodiment the
17 pattern of ligand binding corresponds to those areas
18 exposed to irradiation.

19
20 In another embodiment, irradiation alters the exposed
21 binding moieties. Only the binding moieties which have
22 not been altered by such exposure (that is, only the
23 binding moieties which were not irradiated and which
24 retain their original configuration), are able to bind
25 to the ligand. In this embodiment the pattern of
26 irradiation corresponds to areas not bound by ligand.

27
28 The binding moiety will usually be in its
29 photosensitive form when initially contacted with the
30 linking moiety. However this is not essential and
31 under certain circumstances it may be more convenient
32 to photosensitize a form of the binding moiety in situ
33 after attachment to the linking moiety has taken place.


34
35 The ligand can be any molecule, including proteins,

1 polypeptides, electron mediators, amino acids, sugars,
2 polysaccharides, nucleic acids and other organic or
3 inorganic molecule (and functional equivalents
4 thereof). The ligand may itself be able to bind to a
5 further moiety. For example, the ligand may be an
6 antibody (especially a monoclonal antibody) which may
7 be bound via its Fc region to the binding moiety.
8 Conveniently, the ligand may be a difunctional antibody
9 (especially a monoclonal antibody), that is an antibody
10 having the ability to bind two different haptens
11 separately. Alternatively, the ligand may be an enzyme
12 (or a functional equivalent thereof) or a polynucleic
13 acid.

14
15 In a further embodiment, it is possible to bind two or
16 more different ligands onto the binding moiety in
17 distinct areas. This can be achieved, for example, by
18 irradiation of the surface only in those areas where
19 the first ligand is to be bound. The first ligand is
20 then brought into contact with the irradiated surface,
21 allowed to bind thereto and any excess ligand washed
22 off. The surface may then be selectively exposed to
23 radiation a second time, once the first ligand has
24 bound, thus activating a second selection of binding
25 moieties. A second ligand may be bound to the binding
26 moieties so activated. This process may be repeated as
27 many times as required for each set of ligands to be
28 selectively bound to the surface in a pre-determined
29 way.

30
31 It is possible to coat the binding moieties not reacted
32 to ligand by use of a blocking moiety. Suitable
33 blocking proteins are known in the art, but mention may
34 be made of milk proteins such as casein, TRISTM buffer,
35 or serum albumins such as HSA or BSA.

In a preferred embodiment, the linking moiety may be the tetrameric proteins avidin, streptavidin, functional equivalents or mixtures thereof. Certain avidins and streptavidins have low non-specific binding properties thus eliminating non-specific adsorption. Any other protein or polypeptide with this characteristic will be suitable as a linking moiety in the present invention. It is especially preferred if the binding moiety used therewith is a photosensitive analogue of biotin (vitamin H) which binds to avidin and streptavidin with an association constant of 10^{15}M^{-1} . The photosensitive analogue of biotin may be photobiotin (ie N-(4-azido-2-nitrophenyl)-N'-(N-d-biotinyl-3-aminopropyl-N'-methyl-1,3-propanediamine). Photobiotin contains an arylazide group which is stable in the dark, but upon exposure to ultra-violet or blue light (having a wavelength of 340-375nm) generates highly reactive aryl nitrene group which may bind other molecules. The photobiotin may incorporate a spacer moiety to reduce steric hindrance on binding the ligand. The structure of the spacer-photobiotin molecule is shown in Formula 1 below:



1 The surface to be coated may be any convenient type,
2 including silicon, silicon nitride, silicon dioxide,
3 glass, quartz, metals, metal oxides, polymers including
4 nitrocellulose and nylon, and mixtures thereof.
5 Preferably, the surface is gold, platinum, silicon or
6 silicon oxide, dioxide or nitride and mixtures thereof.

7
8 In a preferred embodiment, the present invention
9 provides a device having a surface, said surface having
10 a ligand arranged thereon in a pre-determined pattern,
11 the binding of said ligand being determined by the
12 irradiation of a photosensitive biotin binding moiety
13 attached to the surface via an avidin linking moiety.
14 The ligand may desirably be an enzyme, for example
15 glucose oxidase, an immunoglobulin, for example an
16 antibody, or a hormone, for example human
17 gonadotrophins.

18
19 The precise binding of a ligand in a pre-determined
20 pattern has many applications. One particularly
21 promising aspect is the use of a surface according to
22 the invention as part of a multi-analyte sensor, in
23 particular a multi-analyte immunosensor. The present
24 invention is particularly suited to this application
25 since each ligand type can be located on the surface
26 with accuracy, eliminating "cross-talk" in the sensor.

27
28 There has been considerable interest over the last
29 decade in the development of amperometric immunoassay,
30 primarily as the technique has the potential to combine
31 the advantages of using a sensitive enzyme label with a
32 convenient and safe format (see Frew et al, Anal Chem
33 59: 933A-944A (1987)). Although there is now an
34 extensive literature in the development of such assays
35 for both clinical and environmental analysis (see

1 "Biosensors", Hall, Wiley (1990)), to date there has
2 been no published description of the fabrication of a
3 true multi-analyte amperometric biosensor, in which
4 more than one high molecular weight species is measured
5 simultaneously by a single device. Of the existing
6 multi-analyte immunosensors, commercial devices that
7 have been produced are qualitative optical assays
8 (based upon agglutination) for low molecular weight
9 analytes (eg the Triage™ and Advisor™ systems (see
10 Buechler et al, Clin Chem 38: 1678-1684; and Parsons et
11 al Clin Chem 39: 1899-1903 (1993)) for detecting drugs
12 of abuse). Such systems are unsuitable for
13 quantitative analysis.

14
15 The use of simultaneous multi-analyte immunoassay is
16 required in a number of clinical situations including
17 the measurement of hormones related with thyroid
18 function and the measurement of gonadotrophins for the
19 investigation of infertility. An example where such an
20 assay would be useful is for the measurement of
21 follicle stimulating hormone (FSH) and luteinising
22 hormone (LH), which can be used as a "fertility test"
23 in women, or to differentiate between primary and
24 secondary hypogonadism. FSH and LH are both
25 glycoprotein hormones, with relative molecular masses
26 of approximately 34,000 and 28,500 respectively.
27 Circulating gonadotrophin concentrations are widely
28 monitored in diagnosis and treatment of infertility, as
29 well as in developmental disorders. For example, in
30 primary hypogonadism, the concentrations of
31 gonadotrophins increase in a process controlled by
32 negative feedback, whereas in secondary hypogonadism
33 low levels of FSH and LH are the cause of the disorder.
34 A particular situation where the use of an immunosensor
35 for the measurement of gonadotrophins is likely to be

1 beneficial, is for *in vitro* fertilisation procedures
2 where the rapid measurement of gonadotrophins is
3 important.
4

5 The major challenge for designing a multi-analyte
6 immunosensor is in developing a technique for
7 patterning of antibodies at discrete transducer sites,
8 ie a method which enables immunologically active IgG to
9 be selectively positioned at particular sites whilst
10 avoiding problems associated with non-specific binding
11 at other sites. Previously a number of methods for
12 immobilising antibodies in such "patterns" on a surface
13 have been reported, although their potential
14 applicability to biosensor technology has been limited
15 by the number of functional proteins that can be
16 patterned and/or by non-specific binding of protein to
17 undesignated areas of the sensor or its surround (see
18 Britland et al, *Biotechnol. Prog.* 8: 155-160 (1992);
19 Bhatia et al, *Anal Biochem*, 208: 197-205 (1993);
20 Connolly, *Trends in Biotechnology* 12: 123-127 (1994)).
21

22 The device according to the invention may also be used
23 to selectively deposit molecules onto a surface in
24 ordered arrays for use in molecular electronics. Thus,
25 groups of molecules may be positioned precisely with
26 respect to other groups of molecules, or to electronic
27 structures in order to build up functional molecular
28 architectures. As is the case for the design of a
29 diagnostic device, a variety of different transducer
30 materials may be used as immobilisation substrates, and
31 the design of arrays that do not exhibit cross-talk is
32 of great importance. Such devices could be used for
33 design of bioelectronic memory cells, or more
34 elaborately, in biological computing.
35

1 A further application of this invention is in a device
2 for the directional propagation of an individual cell,
3 (eg nerve cells or their neurites) on a patterned
4 substrate. In this case, the essential prerequisites
5 are the same as for the design of a diagnostic device,
6 in so much as it is desirable to position organic,
7 inorganic or biological molecules (eg nerve growth
8 factor) onto a pre-defined substrate with no
9 interference from non-specific adsorption. The
10 patterned molecules will act as a chemotactic or
11 topological template for guidance of the cell, which
12 will grow preferentially in a given direction
13 determined by the pattern. Particularly important
14 applications are the manufacture of devices either to
15 control endothelial cell growth for wound healing, or
16 to control nerve cell growth to promote regeneration.

17
18 In addition, it may be desirable to use a patterning
19 technique to alter the behaviour of many cells. For
20 example, by coating appropriate molecules onto a
21 surface, it will be possible to differentially promote
22 or prevent cell growth on the outer surface of a
23 miniature sensor in order to enhance the
24 biocompatibility properties of the device.

25
26 The device according to the present invention is also
27 of utility as a matrix for binding nucleotides, for
28 example DNA or RNA molecules. The nucleotides may be
29 single stranded or double stranded. The nucleotide
30 bound to the device may be used as a probe (for example
31 for nucleotides having a complementary sequence or to
32 bind nucleic acid binding proteins) or may be
33 manipulated by chemical reactions or by genetic
34 engineering techniques. A nucleotide bound to the
35 device according to the invention may be used as a

1 template in a polymerase chain reaction (PCR) method.

2

3 In a further aspect, the present invention provides a
4 process for forming a surface having a ligand bound
5 thereto in a pre-determined pattern, said process
6 comprising the following steps:

7

8 i) binding a linking moiety to a coated or uncoated
9 surface;

10

11 ii) binding a photosensitive binding moiety to said
12 linking moiety;

13

14 iii) selectively exposing said photosensitive binding
15 moiety to irradiation in a pre-determined pattern;

16

17 iv) exposing said binding moiety to said ligand and
18 allowing the ligand to bind to said binding moiety
19 in accordance with the irradiation exposure;

20

21 v) optionally removing excess ligand by washing;

22

23 vi) optionally exposing said ligand to a further
24 molecule capable of binding thereto; and

25

26 vii) optionally repeating steps iii) and iv) with a
27 different ligand.

28

29 Figures 1 to 3 are schematic representations of the
30 process of the present invention.

31

32 Figures 4 to 7 are graphs showing the results of
33 Example 7.

34

35 Figure 4 is a graph showing the electrochemical

1 response (nA) of the disposable multi-analyte sensor to
2 FSH (U l^{-1}) in buffer. There is a linear response at the
3 FSH electrode (o) to FSH over the concentration range
4 0-100 U l^{-1} and there is minimal response at the LH
5 electrode (•) to FSH, indicating low non-specific
6 binding.

7
8 Figure 5 is a graph showing the electrochemical
9 response (nA) of the disposable multi-analyte sensor to
10 LH (U l^{-1}) in buffer. There is a linear response at the
11 LH electrode (•) to LH over the concentration range 0-
12 100 U l^{-1} and there is minimal response at the FSH
13 electrode (o) to LH.

14
15 Figure 6 is a graph showing results for FSH in serum,
16 obtained using the multianalyte immunosensor (as
17 described in Example 7), plotted against those obtained
18 using an established DELFIA technique. Each sample was
19 measured in triplicate and the error bars represent two
20 standard deviations around the mean.

21
22 Figure 7 is a graph showing results for LH in serum,
23 obtained using the multianalyte immunosensor (as
24 described in Example 7), plotted against those obtained
25 using an established DELFIA technique. Each sample was
26 measured in triplicate and the error bars represent two
27 standard deviations around the mean.

28
29 A diagrammatic representation of an example of the
30 process according to the invention is shown in Figures
31 1 and 2 and demonstrates the patterning of three
32 species using avidin as the linking moiety and
33 photobiotin as the binding moiety, and exposing defined
34 areas of the surface to light by the use of a mask.

35

1 Initially, avidin is coated over the entire surface
2 (Step a), photobiotin is then added and binds to the
3 avidin (Step b). Exposure of selected areas to light
4 results in cleavage of the photobiotin molecule (Step
5 c), and when the first ligand to be immobilised is
6 added, specific immobilisation occurs due to reaction
7 with the exposed aryl nitrene group of the cleaved
8 photobiotin.

9
10 After washing off any unbound material, the procedure
11 is repeated with the second ligand to be immobilised
12 (Steps e to g). Again any unbound material is washed
13 off, and the entire surface is then exposed to light
14 (Step h), and a blocking species may be added whose
15 function is to bind to all of the previously unoccupied
16 photobiotin molecules and so block further reactions
17 involving the photobiotin molecule (Step i). Any
18 excess of this blocking species is washed off leaving
19 the surface with the desired pattern of molecules on
20 its surface (Step j).

21
22 Figure 3 is a schematic representation of the
23 immobilisation procedure: (a) Avidin with photobiotin
24 immobilised onto a surface; (b) exposure of selected
25 areas to light through a mask results in activation of
26 the photobiotin molecule, specifically immobilising any
27 protein in the solution; (c) unbound material is
28 removed by washing, and the procedure repeated with a
29 second protein; (d) the entire surface is exposed to
30 light, and a blocking molecule bound to all unreacted
31 photobiotin groups.

32
33 The invention will now be further illustrated by the
34 following, non-limiting examples:

1 Example 1

2

3 (1) Light dependent coupling of glucose oxidase to a
4 gold surface.

5

6 Avidin DTM (Vector Products Ltd, USA) was immobilised on
7 to two identical gold electrodes by placing the
8 electrodes in 5ml of a 0.2mg ml⁻¹ solution of Avidin D
9 in phosphate buffered saline pH 7.4 (PBS) for one hour
10 at ambient temperature. After extensive rinsing with
11 PBS the electrodes were then incubated in 5ml of a 10µg
12 ml⁻¹ solution of long arm photobiotin in PBS for 20
13 minutes under dark room conditions. After extensive
14 rinsings with PBS each electrode had 50µl of identical
15 solutions of glucose oxidase in PBS placed onto it, one
16 electrode was retained in dark room conditions whilst
17 the other was exposed to light from a high pressure
18 mercury vapour lamp for 15 minutes. After extensively
19 rinsing both electrodes with PBS under dark conditions,
20 50µl of a 10 mg ml⁻¹ solution of bovine serum albumin in
21 PBS was added to each electrode and they were exposed
22 to light from a high pressure mercury vapour lamp for
23 15 minutes.

24

25 (2) Assay for glucose oxidase activity

26

27 An amperometric assay was performed using the modified
28 gold surface as a working electrode, with a Ag/AgCl
29 electrode as a reference and a bare platinum flag as a
30 counter electrode. Chronoamperometry was performed in
31 working solutions containing 0 mM and 100 mM glucose
32 solutions in 15mls PBS. The solutions also
33 contained 25 mM KCl as the electrolyte. Initially, the
34 working electrode was poised at a potential of 0V for
35 300 seconds after which the potential was stepped to

1 650mV for 120 seconds during which time the current was
2 monitored.

3

4 Current 30 seconds after
5 application of 650 mV potential
6 μA

7

8 Electrode exposed Electrode
9 to light kept in dark

10

11 0 mM glucose 0.086 0.089

12 100 mM glucose 0.358 0.084

13

14 Example 2

15

16 (1) Light dependent coupling of an antibody to a gold
17 surface

18

19 Avidin D and photobiotin were immobilised onto two gold
20 electrodes according to the process of Example 1.

21 After extensive rinsing with PBS each electrode had
22 50 μl of identical solutions of rabbit anti-rat IgG in
23 PBS placed onto it and they were exposed to light from
24 a high pressure mercury vapour lamp for 15 minutes.

25

26 (2) Assay for antibody activity

27

28 One of the electrodes was placed in 5 ml of 10 $\mu\text{g ml}^{-1}$
29 rat IgG in PBS for 60 minutes, whilst the other was
30 placed in 5 ml of 10 $\mu\text{g ml}^{-1}$ rabbit IgG for 60 minutes.
31 Following this both electrodes were extensively washed
32 with PBS and were incubated in 5 ml of a solution of
33 20 $\mu\text{g ml}^{-1}$ horseradish peroxidase labelled rabbit anti-
34 rat IgG ambient temperature for 60 minutes. An
35 amperometric assay was performed using the modified

1 gold surface as a working electrode, with a Ag/AgCl
2 electrode as the reference and a bare platinum flag as
3 a counter electrode. After thorough rinsing the
4 electrodes were placed in 15ml of 25mM KCL, 10mM
5 hydrogen peroxide, 1mM ferrocene monocarboxylic acid
6 and a potential of 0V was applied for 10 seconds
7 followed by 320 mV for 120 seconds during which time
8 the current was monitored.

9		
10	Sample	Current 30 seconds after
11		application of a 320 mV
12		potential μ A
13		
14	Electrode 1 in PBS	0.079
15	Electrode 2 in PBS	0.083
16	Electrode 1 + Rat IgG	0.243
17	Electrode 2 + Rabbit IgG	0.084

18

19 Example 3

20

21 (1) Light dependent coupling of a protein to a silicon
22 oxide surface

23

24 A wafer of silicon dioxide was immersed in a 1%
25 solution of 1,3-trimethoxysilylpropylethylene diamine
26 in 95% ethanol 5% distilled water for 120 seconds.
27 After removing the wafer from this solution it was
28 rinsed briefly in 95% ethanol 5% distilled water before
29 being heated at 120°C for 30 minutes. The wafer was
30 immersed in a 2% solution of gluteraldehyde in PBS for
31 15 minutes, and then in a solution of 40mM sodium
32 cyanoborohydride, containing 0.2mg ml⁻¹ Avidin D in PBS
33 for 30 minutes at ambient temperature. After extensive
34 rinsing with PBS the wafer was then incubated in 5ml of
35 a 10 μ g ml⁻¹ solution of long arm photobiotin in PBS for

1 20 minutes under dark room conditions. After extensive
2 rinsing with PBS the wafer was covered with a solution
3 of $10\mu\text{g ml}^{-1}$ rabbit IgG and exposed to light from a high
4 pressure mercury vapour lamp for 15 minutes through a
5 chrome mask patterned with grids having lines of width
6 $2\mu\text{m}$, $4\mu\text{m}$, $6\mu\text{m}$ and $8\mu\text{m}$ in equal mark space ratio. After
7 extensive rinsing with PBS the wafer was covered with a
8 solution of 10mg ml^{-1} bovine serum albumin and was
9 exposed to light from a high pressure mercury vapour
10 lamp for 15 minutes.

11

12 (2) Assessment of protein patterning

13

14 The wafer was covered with a solution of $10\mu\text{g ml}^{-1}$ TRITC
15 labelled goat anti-rabbit IgG, for 60 minutes at
16 ambient temperature. After washing in PBS at distilled
17 water the sample was dried in a stream of nitrogen and
18 examined using fluorescent microscopy. Areas of
19 fluorescence were observed which matched the mask that
20 had been used. Features as small as $4\mu\text{m}$ could be
21 resolved.

22

23 Example 4

24

25 (1) Light dependent coupling of two proteins to a 26 silicon dioxide surface

27

28 Avidin D and photobiotin were immobilised onto the
29 silicon dioxide surface as described in Example 3.
30 After extensive rinsing with PBS the wafer was covered
31 with a solution of $10\mu\text{g ml}^{-1}$ rabbit IgG and exposed to
32 light from a high pressure mercury vapour lamp for 15
33 minutes through a chrome mask patterned with a $25\mu\text{m}$
34 grid in equal mark space ratio. After extensive
35 rinsing with PBS the wafer was covered with a solution

1 of 10 μ g ml⁻¹ rat IgG and exposed to light from a high
2 pressure mercury vapour lamp for 15 minutes through the
3 same mask used in Example 3 that had been turned
4 through an angle of 90°. After extensive rinsing with
5 PBS the wafer was covered with a solution of 10mg ml⁻¹
6 bovine serum albumin and was exposed to light from a
7 high pressure mercury vapour lamp for 15 minutes.

8
9 (2) Assessment of protein patterning

10
11 The wafer was covered with a solution of 10 μ g ml⁻¹ TRITC
12 labelled goat anti-rabbit IgG, for 60 minutes at
13 ambient temperature. After extensive rinsing with PBS
14 the wafer was covered with a solution of 10 μ g ml⁻¹ FITC
15 labelled rabbit anti-rat IgG, for 60 minutes at ambient
16 temperature. After washing in PBS and distilled water
17 the sample was dried in a stream of nitrogen and
18 examined using a fluorescent microscope. Unbroken
19 lines of red fluorescence corresponding to the
20 immobilised rabbit IgG were observed, and lines of
21 green fluorescence corresponding to the immobilised rat
22 IgG were observed running perpendicular to the red
23 lines. Where the fluorescent lines crossed the green
24 lines due to rat IgG were discontinued.

25
26 Example 5

27
28 (1) Light dependent coupling of a protein to a glass
29 surface

30
31 A glass wafer was immersed in a 1% solution of 1,3-
32 trimethoxysilylpropylethylene diamine in 95% ethanol 5%
33 distilled water, pH adjusted to 5.0 with glacial acetic
34 acid for 30 seconds. After removing the wafer from
35 this solution it was rinsed briefly in 95% ethanol 5%

1 distilled water before being heated at 120°C for 30
2 minutes. The wafer was immersed in a 2% solution of
3 glutaraldehyde in PBS for 15 minutes, and then in a
4 solution of 40mM sodium cyanoborohydride, 0.2mg ml⁻¹
5 Avidin D in PBS for 30 minutes at ambient temperature.
6 After extensive rinsing with PBS the wafer was then
7 incubated in 5ml of a 10µg ml⁻¹ solution of long arm
8 photobiotin in PBS for 20 minutes under dark room
9 conditions. After extensive rinsing with PBS the wafer
10 was covered with a solution of 10µg ml⁻¹ rat IgG and
11 exposed to light from a high pressure mercury vapour
12 lamp for 15 minutes through a patterned chrome mask.
13 After extensive rinsing with PBS the wafer was covered
14 with a solution of 10mg ml⁻¹ bovine serum albumin and
15 was exposed to light from a high pressure mercury
16 vapour lamp for 15 minutes.

17 (2) Assessment of protein patterning

18 The wafer was covered with a solution of 10µg ml⁻¹ FITC
19 labelled anti-rat IgG, for 60 minutes at ambient
20 temperature. After washing in PBS and distilled water
21 the sample was dried in a stream of nitrogen and
22 examined using fluorescent microscopy. Areas of
23 fluorescence were observed which matched the mask that
24 had been used.

25 Example 6

26 Cell Guidance

27 (1) Patterning of silicon surface

28 A wafer of silicon dioxide was immersed in a 1%
29 solution of 1,3-trimethoxysilylpropyl- ethylene diamine
30
31
32
33
34
35

1 in 95% ethanol 5% distilled water for 120 seconds.
2 After removing the wafer from this solution it was
3 rinsed briefly in 95% ethanol 5% distilled water before
4 being heated at 120°C for 30 minutes. The wafer was
5 immersed in a 2% solution of gluteraldehyde in PBS for
6 15 minutes, and then in a solution of 40mM sodium
7 cyanoborohydride, containing 0.2 mg ml⁻¹ Avidin D in PBS
8 for 30 minutes at ambient temperature. After extensive
9 rinsing with PBS the wafer was then incubated in .5ml
10 of a 10 µg ml⁻¹ solution of long arm photobiotin in
11 PBS for 20 minutes under dark room conditions. After
12 extensive rinsing with PBS the wafer was covered with a
13 sterile solution of 10 mg ml⁻¹ concanavalin A and
14 exposed to light from a high pressure mercury vapour
15 lamp for 15 minutes through a chrome mask patterned
16 with a 12.5 µm grid . After extensive rinsing with PBS
17 the wafer was covered with a sterile solution of 10mg
18 ml⁻¹ bovine serum albumin and was exposed to light from
19 a high pressure mercury vapour lamp for 15 minutes.

20

21 (2)

22

23 Snails were by placed in 25% Listerine for 5 minutes,
24 and their brains were dissected out and incubated in 1
25 mg ml⁻¹ Pronase at ambient temperature for 90 minutes.
26 Individual cells were isolated and placed onto the
27 patterned silica wafer in growth media consisting of
28 33% (v/v) Gibco L-15, but with the CaCl₂ and MgCl₂
29 concentrations adjusted to 5.5mM and 2.43 mM
30 respectively. The growth media also had additions of
31 50 µg ml⁻¹ gentamycin and 0.2% glucose (w/v). The cells
32 were incubated at 20°C for 7 days.

33

34 (3) Assessment of cell guidance.

35

1 The cells were examined under a microscope. Cell
2 processes were to seen to run parallel with each other,
3 and the distance between the processes was consistent
4 with the patterning of the protein on the silicon
5 dioxide.

6
7 Example 7

8
9 Multianalyte Sensor

10

11 In this example a multianalyte immunosensor for the
12 quantitative determination of the human gonadotrophin
13 hormones (follicle stimulating hormone and luteinising
14 hormone) is produced. The assay is based upon the
15 electrochemical detection of two horseradish peroxidase
16 labelled antibodies using a ferrocene mediated system.
17 Results obtained with the biosensor showed a good
18 correlation with those obtained using an established
19 clinical diagnostic technique based upon dissociation-
20 enhanced lanthanide fluorometric immunoassay.

21

22 EXPERIMENTAL

23

24 Electrode Fabrication

25

26 Sensor arrays were produced on 10 cm diameter silicon
27 wafers. Immobilisation of proteins was performed
28 before the wafer was cut into individual devices, so
29 that the preparation of all arrays was identical. Gold
30 electrodes were prepared using standard
31 photolithographic procedures. Both the electrodes and
32 bonding pads were exposed whilst all other areas were
33 electrically insulated using hardened photoresist.
34 Ag/AgCl reference electrodes were prepared by
35 electrosorbption of silver onto specified gold

1 electrodes from a solution of 0.1M AgNO₃ in 0.1M
2 sulphuric acid with a silver anode (at a constant
3 current of 0.4mA cm⁻² for 6 hours) followed by
4 chloridisation in 0.1M HCl (0.4 mA cm⁻² for 30 minutes).
5 The electrochemical behaviour of the fabricated
6 electrodes was verified using cyclic voltammetry (-0.2
7 to +0.75 V scanned at 20 mV s⁻¹) in 0.2 mM ferrocene
8 monocarboxylic acid (Sigma, Poole, England) containing
9 50 mM Tris 50 mM KCl, pH 7.4. Results were compared
10 with those obtained using a Bioanalytical Systems (BAS)
11 gold working electrode and a BAS RE4 Ag/AgCl reference
12 electrode (Biotech Instruments Ltd, Luton, England).
13 Reproducibility of electrode arrays prepared in this
14 manner, was assessed by measuring the
15 chronoamperometric response (10 seconds at 0V, 120
16 seconds at +650 mV) in the presence of 0.5 mM H₂O₂ in 50
17 mM sodium phosphate buffer containing 50 mM KCl, pH
18 7.4. All experiments involving the fabrication and
19 characterisation of electrodes were performed using an
20 EG&G 273A potentiostat (EG&G, Sunninghill, England).

21

22 Antibody Immobilisation

23

24 The immobilisation procedure is outlined in Figure 3.
25 Neutravidin™, a modified form of avidin (Pierce and
26 Warriner, Chester, UK) was attached to the gold
27 electrode surface using activation of a self-assembled
28 thiol monolayer (in this case N-acetyl-l-cysteine
29 (Sigma)) with a water soluble carbodiimide. Electrode
30 arrays were first incubated in 2 mM N-acetyl-l-cysteine
31 in 10 mM phosphate buffer (pH 7.0) for 120 minutes at
32 ambient temperature, followed by 120 minutes incubation
33 in 1% (w/v) 1-ethyl-3-(3-dimethylaminopropyl)-
34 carbodiimide (EDC) (Sigma) in 10 mM phosphate buffer
35 (pH 7.0). The modified gold sensor arrays were then

1 incubated in 100Ag ml⁻¹ Neutravidin in 10 mM phosphate
2 buffer (pH 7.0) for 16 hours at 4°C. All subsequent
3 stages of the immobilisation procedure were performed
4 at ambient temperature. After washing in phosphate
5 buffered saline (10 mM sodium phosphate, 137 mM NaCl,
6 2.7 mM KCl), pH 7.4 (PBS), the electrodes were
7 incubated first in 10 mg ml⁻¹ casein in PBS for 60
8 minutes and then in 10 µg ml⁻¹ long arm photobiotin
9 (Vector Laboratories, Peterborough, England) in PBS,
10 for 20 minutes in the dark. All subsequent
11 immobilisation stages were performed in a dark room.
12 After washing in PBS, the wafer was covered with 10 Ag
13 ml⁻¹ monoclonal anti-FSH (Biogenesis Ltd, Bournemouth,
14 England, clone BIO-FSHB-003), and selected electrodes
15 were exposed to light from a 100W HG-10101AF super high
16 pressure mercury vapour lamp (Nikon, Tokyo, Japan) 185
17 mm from the electrodes for 15 minutes (Irradiance = 9
18 mW cm⁻²) using a suitable mask. It is important to note
19 that light of wavelengths below 300 nm was removed by
20 passing through a glass filter to prevent denaturation
21 of proteins.

22

23 After washing in PBS, the wafer was covered with 10 µg
24 ml⁻¹ monoclonal anti-LH (Biogenesis clone LH-007), and
25 selected electrodes were exposed to light from the lamp
26 for 15 minutes, prior to washing in PBS. The entire
27 wafer was exposed to light from the lamp for 15 minutes
28 in the presence of 10 mg ml⁻¹ casein in PBS, and washed
29 in PBS.

30

31 Immunoassay procedure

32

33 The immunoassay, which was an enzyme linked
34 immunosorbent assay (ELISA) based upon a "sandwich"
35 format, was configured with immobilised "capture"

1 antibodies on the electrode surfaces such that the
2 addition of a second enzyme labelled antibody was
3 directed against a second epitopic site on the antigen.
4 Sensors were incubated with 250 μ l of sample for 60
5 minutes, washed thoroughly with PBS, and incubated in a
6 mixture of 10 μ g ml^{-1} horseradish peroxidase (HRP)
7 labelled anti-LH (Biogenesis clone BIO-FSHB-002) and 10
8 μ g ml^{-1} HRP labelled anti-LH (Biogenesis clone LH-005)
9 in PBS for 60 minutes at ambient temperature, before,
10 finally, being washed in PBS. Simultaneous assessment
11 of HRP activity at the FSH and LH sensor electrodes was
12 performed chronoamperometrically using two
13 Bioanalytical System CV-37 potentiostats (Biotech
14 Instruments Ltd, Luton, England) and a Goerz SE120 dual
15 channel chart recorder (Belmont Instruments, Glasgow,
16 UK). Activity was determined at +150 mV vs Ag/AgCl by
17 measuring the current produced after 20 seconds in the
18 presence of 10 mM hydrogen peroxide and 0.2 mM
19 ferrocene monocarboxylic acid in 50 mM phosphate buffer
20 containing 50 mM KCl, pH 7.4. The response of the
21 immunosensor to hormone concentration in a buffered
22 aqueous solution was measured by preparation of a
23 series of standards (0 - 100 U l^{-1}) of FSH and LH
24 (Biogenesis) which covered the concentration range of
25 clinical interest. The results obtained were
26 subsequently used to construct a calibration curve for
27 further experiments.

28
29 The multi-analyte immunosensor was used to determine
30 gonadotrophin concentrations in 10 serum samples from
31 hospital outpatients. The analyses were performed on
32 three separate occasions using a newly constructed
33 calibration curve each time. The results obtained were
34 compared with those obtained using an established
35 DELFIA technique (see Lovgren et al Talanta 31: 909-916

1 (1984)). The samples examined covered the range of
2 values typically seen in clinical laboratories.

3

4 RESULTS AND DISCUSSION

5

6 Patterning of Antibodies on Electrode Surfaces

7

8 Central to designing a multianalyte immunosensor is
9 overcoming the problem of patterning of antibodies at
10 discrete locations without encountering high levels of
11 non-specific binding. In this example this difficulty
12 has been overcome by using biological self-assembly of
13 avidin and a biotin derivative, called photobiotin.
14 The first stage of the patterning technique therefore
15 involves immobilising either avidin or its microbial
16 counterpart streptavidin onto a surface. Both of these
17 are tetrameric proteins that specifically bind biotin
18 with an association constant of 10^{15} M^{-1} . Photobiotin is
19 bound to the avidin-modified surface to provide a light
20 sensitive "addressable" surface onto which molecules
21 can be "written" using an appropriate light source and
22 a mask. Photobiotin contains an aryl azide group which
23 is stable in the dark, but which, upon exposure to
24 light (340-375 nm) forms a highly reactive aryl nitrene
25 group. This will bind organic species present in the
26 solution above the surface by a number of mechanisms
27 including insertion into C-H or N-H bonds, and addition
28 to C=C bonds. After immobilisation of the avidin, the
29 surface was exposed to a solution of photobiotin which
30 bound to the avidin-modified surface (Fig. 3a).
31 Exposure of selected areas of this surface to light
32 resulted in activation of the photobiotin molecule
33 (Fig. 3b), so that antibodies present in the solution
34 were immobilised onto the surface. To minimise the
35 problem of non-specific binding of proteins at the

1 avidin modified surface, a modified form of avidin
2 (Neutraavidin) which has low non-specific binding
3 characteristics was used. Consequently, few protein
4 molecules adhere to the surface non-specifically
5 compared with the number that are bound by activated
6 photobiotin. Any unbound material can be removed by
7 washing. The patterning procedure can be repeated
8 sequentially with a second protein (Fig. 3c) or with
9 any number of proteins thereafter. In order to ensure
10 that all unreacted photobiotin groups are
11 "neutralised", the entire surface is exposed to light
12 in the presence of a blocking molecule (eg casein or
13 bovine serum albumin) (Fig. 3d).

14 15 Characterisation of Electrodes

16
17 The potentials at which oxidation and reduction peaks
18 were evident upon cyclic voltammetry of ferrocene
19 monocarboxylic acid for the fabricated electrodes were
20 within 5 mV of those obtained when using standard BAS
21 working and reference electrodes ($E_{pa} = 355$ mV, $E_{pc} = 296$
22 mV). The intra-batch coefficient of variation for the
23 responses of the electrode arrays to 0.5 mM H_2O_2 was
24 1.86% (n=20), whilst the interbatch coefficient of
25 variation was 2.43% (n=5).

26 27 Immunosensor Response

28
29 The response of the sensor to FSH and LH in buffer was
30 measured over the range 0 to 100 $U l^{-1}$, Figures 4 and 5.
31 When corrected for the specific activities of the
32 hormone preparations, these ranges are equivalent to 0
33 to 26 $ng l^{-1}$ and 0 to 18 $ng l^{-1}$ for FSH and LH
34 respectively. Figure 4 demonstrates that the current
35 at the FSH sensor is proportional to the FSH

1 concentration (2.1 nA / UI^{-1} (8.0 nA/ngl^{-1})), and that the
2 response of the LH sensor to FSH is negligible (0.07
3 nA/UI^{-1} (0.38 nA/ngl^{-1})). Likewise, Figure 5
4 demonstrates that the current produced by the LH sensor
5 is proportional to the LH concentration (2.5 nA / UI^{-1}
6 ($13.6 \text{ nA / ng l}^{-1}$)), and the response of the FSH sensor
7 to LH is negligible ($0.11 \text{ nA / UI}^{-1}$ ($0.42 \text{ nA / ngl}^{-1}$)).

8
9 The response when no antigen is present is due to a
10 number of factors, chief amongst these is the current
11 resulting from electrochemical processes unrelated to
12 the immunoassay (ie the background current obtained
13 when there is no enzymic activity). The remainder of
14 the current measured, when the antigen concentration is
15 zero, is due either to non-specific binding or to
16 diffusion of electroactive species between electrodes.

17
18 Of the several causes of non-specific binding, the
19 binding of an inappropriate antibody at a sensor site
20 (eg anti-LH on a sensor for FSH) is of particular
21 importance in a multianalyte immunosensor. This can
22 occur for a number of reasons, such as binding through
23 non-specific protein-protein interactions, hydrophobic
24 interactions with non-polar surfaces, or electrostatic
25 interactions between the protein and the surface, and
26 results in an inappropriate antibody being able to bind
27 its complimentary antigen and the enzyme labelled
28 second antibody.

29
30 Figures 6 and 7 show results for human serum samples
31 obtained from the multianalyte sensor compared with
32 those from an established DELFIA technique. This
33 latter method uses lanthanides (which have a relatively
34 long lived fluorescence) such as europium as
35 fluorescent labels in immunoassays. The intensity of

1 the fluorescence is enhanced by dissociating the label
2 from the immunocomplex prior to measurement. There is
3 a very good correlation between the two methods, and
4 close agreement between results at all concentrations
5 for both FSH ($[FSH]_{\text{IMMUNOSENSOR}} = 0.9756 [FSH]_{\text{DELPIA}} + 0.332$,
6 $r^2 = 0.9990$) and, LH ($[LH]_{\text{IMMUNOSENSOR}} = 0.9815 [LH]_{\text{DELPIA}} +$
7 0.125 , $r^2 = 0.9996$).

8

9 Conclusion

10

11 The immobilisation procedure described enables the
12 selective and specific patterning of multiple
13 functional proteins with minimal non-specific binding.
14 The process has the potential to be miniaturised with
15 micrometre resolution and therefore may be used to
16 produce multianalyte microensors.

17

18 The applicability of this technique to multianalyte
19 immunoassays has been demonstrated using determination
20 of gonadotrophins as a model system. Although a sensor
21 for measuring two analytes has been constructed, the
22 technology that has been developed is compatible with
23 the fabrication of a sensor for a greater number of
24 analytes. The fabrication and immobilisation
25 procedures used in this work would be compatible with
26 manufacturing technology commonplace in the
27 microelectronics industry. Additionally, there is no
28 waste of expensive proteins such as monoclonal
29 antibodies as non-immobilised excess protein can easily
30 be recovered, and be reused.

31

32 Example 8

33

34 Patterning of Nucleic Acids

35

1 A SiO₂ wafer was immersed in 1% 1,3-trimethoxysilyl-
2 propylethylene diamine in 95:5 (v/v) ethanol/distilled
3 water for 120 seconds and briefly rinsed in 95:5 (v/v)
4 ethanol/distilled water before heating at 120°C for 30
5 minutes. The wafer was immersed in 2% gluteraldehyde
6 in phosphate buffered saline (10 mM sodium phosphate,
7 137 mM NaCl, 2.7 mM KCl, pH 7.4 (PBS)) for 15 minutes,
8 and in 40 mM sodium cyanoborohydride, 0.2mg ml⁻¹
9 Neutravidin™ (Pierce & Warriner, Chester, UK) in PBS
10 for 30 minutes. The SiO₂ substrate was washed in PBS
11 after this and all subsequent steps. The avidin-
12 modified wafer was incubated in 5 ml of 10 µg ml⁻¹ long
13 arm photobiotin (Vector) in PBS for 20 minutes, this
14 and all subsequent stages were performed under dark
15 room conditions.
16
17 A solution of biotinylated DNA in PBS, was layered on
18 to the SiO₂ wafer and a photolithographic mask with 3 µm
19 lines (equal mark-space ratio) was placed on top. The
20 sample was then exposed to light from a 100W high
21 pressure mercury vapour lamp for 15 minutes (irradiance
22 = 9 mW cm⁻²). Following exposure, the mask was removed
23 and it and the wafer were thoroughly washed with PBS.
24
25 The sample was incubated in fluorescein isothiocyanate
26 (FITC) labelled avidin for 2 hours, dried under a
27 gentle stream of nitrogen and examined using
28 fluorescence microscopy. A pattern corresponding to
29 that of the photolithographic mask was observed.
30
31 Modifications and variations of the above described
32 embodiments can be adopted without departing from the
33 scope of the invention.

1 **Claims**

2

3 1. A device having a surface, said surface having a
4 ligand bound thereto in a pre-determined pattern,
5 the binding of said ligand being determined by the
6 irradiation or non-irradiation of a photosensitive
7 binding moiety attached to said surface via a
8 linking moiety.

9

10 2. A device as claimed in Claim 1 wherein two or more
11 ligands are bound to said surface.

12

13 3. A device as claimed in either one of Claims 1 and
14 2 which produces a measureable change.

15

16 4. A device as claimed in any one of Claims 1 to 3
17 wherein said linking moiety is avidin or a
18 functional equivalent thereof.

19

20 5. A device as claimed in any one of Claims 1 to 4
21 wherein said photosensitive binding moiety is
22 photobiotin or a functional derivative thereof.

23

24 6. A device as claimed in any one of Claims 1 to 5
25 wherein said ligand is a hormone, an enzyme or an
26 immunoglobulin.

27

28 7. A device as claimed in any one of Claims 1 to 6
29 wherein substantially all of the photosensitive
30 binding moiety not bound to ligand is bound to a
31 blocking protein.

32

33 8. A device as claimed in any one of Claims 1 to 7
34 wherein the surface is silicon, silicon nitride,
35 silicon dioxide, glass, quartz, metals, metal

1 oxides, polymers and/or mixtures thereof.

2

3 9. A device as claimed in any one of Claims 1 to 8
4 for use in a multi-analyte sensor, in molecular
5 electronics, in binding nucleotides, in
6 directional propagation of cells, and/or in
7 alteration of cell behaviour.

8

9 10. Use of a device as claimed in any one of Claims 1
10 to 8 in a multi-analyte sensor.

11

12 11. Use as claimed in Claim 10 in a multi-analyte
13 immunosensor.

14

15 12. Use of a device as claimed in any one of Claims 1
16 to 8 in molecular electronics.

17

18 13. Use of a device as claimed in any one of Claims 1
19 to 8 in directional propagation of cells.

20

21 14. Use of a device as claimed in any one of Claims 1
22 to 8 in the alteration of cell behaviour.

23

24 15. An immunosensor comprising a device as claimed in
25 any one of Claims 1 to 8.

26

27 16. A multi-analyte immunosensor comprising a device
28 as claimed in any one of Claims 1 to 8.

29

30 17. An electronics device comprising a device as
31 claimed in any one of Claims 1 to 8.

32

33 18. Cells obtained by propagation using a device as
34 claimed in any one of Claims 1 to 8.

35

- 1 19. A process for forming a surface having a ligand
2 bound thereto in a pre-determined pattern, said
3 process comprising the following steps:
4
- 5 i) binding a linking moiety to a coated or uncoated
6 surface;
7
- 8 ii) binding a photosensitive binding moiety to said
9 linking moiety;
10
- 11 iii) selectively exposing said photosensitive binding
12 moiety to irradiation in a pre-determined pattern;
13
- 14 iv) exposing said binding moiety to said ligand and
15 allowing the ligand to bind to said binding moiety
16 in accordance with the irradiation exposure;
17
- 18 v) optionally removing excess ligand by washing; and
19
- 20 vi) optionally exposing said ligand to a further
21 molecule capable of binding thereto.
22
- 23 20. A process as claimed in Claim 19 wherein steps
24 iii) and iv) are repeated at least once to bind a
25 second ligand to said surface in a pre-determined
26 pattern.
27
- 28 21. A process as claimed in either one of Claims 19
29 and 20 wherein substantially all of the
30 photosensitive binding moiety not bound to ligand
31 is subsequently bound to a blocking moiety.
32
- 33 22. A process as claimed in any one of Claims 19 to 21
34 wherein selective irradiation or non-irradiation
35 of said photosensitive binding moiety is achieved

1 by use of a mask.


2

3 23. Use of a device as claimed in any one of Claims 1
4 to 8 for diagnosis.


5

6 24. Use of a device as claimed in any one of Claims 1
7 to 8 for binding nucleotides.


1/7

Figure 1

2/7

Figure 2

3/7

Figure 3

□ = avidin

● = 1st protein


○ = photobiotin

▲ = 2nd protein

○ = blocking species


SUBSTITUTE SHEET (RULE 26)

4/7

Figure 4


SUBSTITUTE SHEET (RULE 26)

5/7

Figure 5


SUBSTITUTE SHEET (RULE 26)

6/7

Figure 6

SUBSTITUTE SHEET (RULE 26)

7/7

Figure 7

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 94/02680

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 6 G01N33/543 G01N33/547 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	JOURNAL OF IMMUNOLOGICAL METHODS., vol.132, 1990, NEW YORK US pages 91 - 101 W. EMLÉN ET AL. 'A NEW ELISA FOR THE DETECTION OF DOUBLE-STRANDED DNA ANTIBODIES.' see the whole document ---	1-24
Y	EP,A,0 127 438 (NATIONAL RESEARCH DEVELOPMENT CO.) 5 December 1984 cited in the application see the whole document & GB,A,2 141 544 ---	1-24
A	WO,A,91 07087 (AFFYMAX TECHNOLOGIES, N. V.) 30 May 1991 ---	
	--- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- * "A" document defining the general state of the art which is not considered to be of particular relevance
- * "E" earlier document but published on or after the international filing date
- * "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- * "O" document referring to an oral disclosure, use, exhibition or other means
- * "P" document published prior to the international filing date but later than the priority date claimed

* "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

* "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

* "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

* "&" document member of the same patent family

Date of the actual completion of the international search

19 April 1995

Date of mailing of the international search report

10.05.95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax (+31-70) 340-3016

Authorized officer

Cartagena y Abella,P

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 94/02680

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>NUCLEIC ACIDS RESEARCH, vol.13, no.3, 1985, ARLINGTON, VIRGINIA US pages 745 - 761 A.C. FORSTER ET AL. 'NON-RADIOACTIVE HYBRIDIZATION PROBES PREPARED BY THE CHEMICAL LABELLING OF DNA AND RNA WITH A NOVEL REAGENT, PHOTOBIOITIN.' -----</p>	

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 94/02680

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0127438	05-12-84	CA-A- 1229883	01-12-87
		DE-A- 3468146	28-01-88
		GB-A, B 2141544	19-12-84
		JP-B- 6050316	29-06-94
		JP-A- 59225343	18-12-84
		US-A- 4562157	31-12-85

GB-A-2141544	19-12-84	CA-A- 1229883	01-12-87
		DE-A- 3468146	28-01-88
		EP-A, B 0127438	05-12-84
		JP-B- 6050316	29-06-94
		JP-A- 59225343	18-12-84
		US-A- 4562157	31-12-85

WO-A-9107087	30-05-91	AU-A- 6886791	13-06-91
		EP-A- 0502060	09-09-92
		JP-T- 5501611	25-03-93
		US-A- 5252743	12-10-93
